

Results of the ADHERE Upper Airway Stimulation Registry and Predictors of Therapy Efficacy

ADHERE Registry Summary (n=1,017 enrolled)

E Thaler, R Schwab, J Maurer, et al

Laryngoscope, Sept 2019

[Publication Link \[open access\]](#)


OSA Treatment Background



While CPAP is the gold standard treatment of OSA, 30-50% cannot tolerate CPAP¹



Untreated OSA associated with daytime sleepiness, higher cardiovascular risk



There is a need for treatment options for CPAP-intolerance




Upper Airway Stimulation – surgical option, shown to be safe and effective in multiple studies

Inspire Therapy

A Treatment for Obstructive Sleep Apnea Patients Who Are Unable to Use CPAP


Safe Outpatient Procedure



Sleep Remote



Nightly Adherence Monitoring (Quality Measures)




ADHERE Registry

- Goal: Collect **real-world outcomes** data
- International multi-center, standard-of-care registry
- Eligibility – prospective patients receiving UAS for OSA
 - CPAP intolerant or non-compliant
 - AHI between 15-65, and fewer than 25% central apneas
 - Absence of velum complete concentric collapse on DISE


1,400 enrollments as of Sept 2019

Enrollment Goal: 2,500 patients

36 SITES IN THE US & EUROPE



Registry Data Collection Follows Clinical Protocol



AHI: apnea-hypopnea index (4%);
ESS: Epworth sleepiness scale;
AE: adverse event;
PSG: in-lab polysomnography;
HSAT: home sleep apnea test


Study Enrollment Status

At Manuscript Completion

- Study is on-going, continues to capture data through patient follow-up
- This paper (n=1,017) extends the work from ADHERE-500¹

ENROLLMENT STATUS

Oct 2016 – Feb 2019



1. Heiser, Eur Resp J 2019

ADHERE Registry Goals

Report outcomes and new findings



UPDATE CLINICAL OUTCOMES
(AHI, ESS, USAGE) AND SAFETY



DISSEMINATE NEW FINDINGS
AS ENROLLMENTS PROGRESS

ADHERE Registry


Demographics: middle aged, male, severe OSA (n=1,017)

Patient Characteristics	Value
Age	60 ± 11 (22-86)
Sex	74% Male
Ethnicity	96% Caucasian
Body Mass Index	29.3 ± 3.9
Baseline AHI	36 ± 15

Baseline Co-morbidities	Value
Hypertension	47%
Depression	22%
Diabetes	13%
Atrial Fibrillation	6%
Heart Attack	4%
Stroke	3%


ADHERE Registry: Consistent effectiveness

Apnea Hypopnea Index (AHI)



Mean AHI reduced from baseline of 35.8 ± 15.4 to 14.2 ± 15.0 at 12 months ($p < 0.001$)

Epworth Sleepiness Scale (ESS)




Mean ESS reduced from baseline of 11.4 ± 5.6 to 7.2 ± 4.8 at 12 months
Reference: ESS < 10 considered free of symptoms for excessive daytime sleepiness

ADHERE Registry: Strong safety profile

Type	Post-Titration		Final Visit	
	# of Events	% of Patients	# of Events	% of Patients
Tongue Weakness	3	<1%	0	-
Swallowing or speech related	4	1%	1	<1%
Discomfort (incision/scar)	14	4%	8	2%
Discomfort (device)	10	3%	5	1%
Infection	2	<1%	0	-
Post-Op – Other	14	4%	6	2%
Stimulation related discomfort	41	12%	28	8%
Tongue abrasion	12	3%	14	4%
Insomnia/Arousal	10	3%	17	5%
Revision interventions (including explant)	1	<1%	2	<1%
Other Discomfort	12	3%	8	2%
Activation - Other	37	3%	23	7%
Total	161	46%	113	32%

Adhere Registry Physician Global Impression:


92% of patients had improvement at 12-months



High Patient Satisfaction


How does Inspire compare against your previous experience with CPAP? (n=378)

95%




Given the chance, I would choose to receive Inspire again (n=390)

94%




I would recommend Inspire to a friend or family member (n=390)

96%




Overall, how satisfied are you with Inspire? (n=391)

93%



High Patient Adherence

Usage of 5.6 hr/night is higher than CPAP clinical trials




1. ADHERE-1000: Thaler, Laryngoscope 2019
2. APPLES: Kushida, Sleep 2012
3. SAVE: McEvoy, NEJM 2016
4. Medicare PAP "guideline" is 4 hours / night, 5 nights per week, within a 30 consecutive day period


Improved understanding of approaching the hypoglossal nerve

Locating digastric & mylohyoid can prevent “mistaken identity” of mylohyoid nerve vs. hypoglossal nerve

Previous understanding – digastric runs horizontal



Current understanding –digastric fibers run more vertical




Example: Clinica Navarra Case Report of mistaken nerve

Introduction

Surgical challenges during hypoglossal nerve stimulation surgery aren't common and they are usually related to identification of the medial division branches. We report an unusual case of an undescribed setback in which the mylohyoid nerve was confused for the hypoglossal nerve.


Clinical Case

62-year old man with a five-year history of OSA, with CPAP intolerance. A body mass index (BMI) of 24, an Epworth Sleepiness Scale 9/24, and AHI of 47/hour, and history of tonsillectomy during childhood. Physical examination, awake endoscopy and drug-induced sleep endoscopy (DISE) revealed an antero-posterior soft palate and tongue base collapse. Having met surgical implantation criteria, upper airway stimulation surgery and an Inspire system implant were indicated.



This illustration represents where we found the mylohyoid nerve, normally it is located more superiorly, it runs forward and inferiorly along the inner aspect of the mandibular ramus and curves anteriorly to travel within the mylohyoid ridge.

- Mylohyoid nerve (MHN) runs along the mylohyoid muscle, similar path as HGN, but is smaller in caliber
- NIM testing of mylohyoid can also appear to have tongue protrusion
- Hypoglossal nerve (HGN) is deep to the mylohyoid muscle
- Clear identification of muscle layers can avoid 'mistaken identity' of MHN for HGN



Post-hoc predictors of therapy response

- **Multiple ways to define response to therapy**
(AHI, ESS, usage, or combination of these)
- **Sleep surgeons measure success by the “Sher Response Rate”**
 - 50% decrease in AHI, and ≤ 20 events/hour
- **STAR 1-year responder rate: 66%**
- **ADHERE-1000 1-year responder rate: 69%**
- **Can we identify potential predictors of increased response?**


All subpopulations showed significant success

Females, and lower BMI had greater magnitude improvement

- Univariate / multi-variate regression of demographics vs. AHI response (Sher Criterion)
- Predictors of highest success were:
 - Female Gender - 94% increased odds of favorable response vs males (ie, 80% vs 67% Response)
 - Lower BMI - every 1pt. decrease in BMI associated with 8% higher odds of favorable AHI response
- Age nor baseline AHI did not predict response
- Suggests a biological mechanism or phenotype that is more sensitive to UAS


These are retrospective findings and not intended to change patient selection

Univariate model for therapy response




Therapy response is defined as at least 50% reduction of AHI to less than 20.

Both genders had significant reduction in AHI



ADHERE Registry Update Summary



Largest real-world data collection of upper airway stimulation for treatment of OSA to date



Reduced OSA severity, sustained through 12-months, **consistent** with multiple other studies



Improved patient symptoms, and **high satisfaction**



Maintained high therapy **adherence** after 12 months

Supplementary Details

Multi-variate model with stepwise selection – gender and BMI were retained as predictors

Parameter	Univariable Results		Multivariable Results Full Model		Multivariable Results Reduced Model	
	OR (p-value)	95% CI for OR	OR (p-value)	95% CI for OR	OR (p-value)	95% CI for OR
Sex (Female vs Male)	<u>1.943 (0.0457)</u>	<u>1.013, 3.729</u>	<u>3.634 (0.0041)</u>	<u>1.505, 8.772</u>	<u>3.413 (0.0049)</u>	<u>1.452, 8.019</u>
Age at consent	1.014 (0.1862)	0.993, 1.034	1.000 (0.9998)	0.976, 1.025		
BMI at baseline	<u>0.915 (0.0028)</u>	<u>0.863, 0.970</u>	<u>0.913 (0.0108)</u>	<u>0.851, 0.979</u>	<u>0.909 (0.0050)</u>	<u>0.851, 0.972</u>
Baseline AHI	0.993 (0.2914)	0.979, 1.006	1.006 (0.5198)	0.988, 1.024		
Tongue motion	P = 0.6414		P = 0.3795			
Bilateral protrusion vs. Right protrusion	1.312 (0.3488)	0.743, 2.318	1.554 (0.1645)	0.835, 2.894		
Bilateral or right protrusion vs. Other	0.963 (0.9244)	0.442, 2.100	-	-		
Other vs. Right protrusion	1.284 (0.5843)	0.525, 3.141	1.339 (0.6320)	0.406, 4.415		
Therapy hours per week at 6-mo	1.011 (0.2457)	0.993, 1.029	1.004 (0.8103)	0.971, 1.038		
<28 hours vs ≥28 hours at 6-months	0.726 (0.3864)	0.352, 1.498	1.130 (0.8362)	0.355, 3.592		
Therapy hours per week at 12-mo	1.017 (0.0390)	1.001, 1.033	1.001 (0.9668)	0.969, 1.034		
<28 hours vs ≥28 hours at 12-months	0.622 (0.0769)	0.367, 1.053	0.651 (0.3732)	0.254, 1.673		

- Gender, baseline BMI, and binary therapy use (<28 hours vs ≥28 hours) at final follow-up were entered into the model in the first, second, and third step. No other variable met the chi-square score of 0.2 significance level for entry into the model.